Cagrilintide storage and stability: lyophilized peptide handling
Removing water slows most chemical degradation, which is why Cagrilintide is supplied lyophilized. Moisture, temperature cycling and light still matter, and peptides in solution degrade faster than dry powder.
Lyophilized peptides are considerably more stable than peptides in solution, but they are not immune to change. This article explains why Cagrilintide is supplied freeze-dried, the chemical and physical pathways by which peptides degrade, how those pathways apply to the Cagrilintide sequence, and the storage and handling practices that limit them.
Why peptides are supplied lyophilized
Many degradation reactions in peptides, including hydrolysis and deamidation, require water or proceed far faster in solution. Lyophilization removes water by freezing the material and then sublimating the ice under vacuum. The result is a dry solid that is generally much more stable than the same peptide in solution.1,2 Cagrilintide is recorded as a white lyophilized powder on every certificate.
Chemical and physical degradation
Reviews of protein and peptide stability divide degradation into two groups.2,3 Chemical changes alter covalent bonds: a new molecule is formed, usually with a different mass. Physical changes alter structure or association without breaking covalent bonds, for example aggregation or adsorption to container surfaces.
The main pathways and the Cagrilintide sequence
| Pathway | Residues mainly involved | In the Cagrilintide sequence |
|---|---|---|
| Oxidation | Met, Cys, Trp, His | Cys2, Cys7; His18 |
| Deamidation | Asn (fast), Gln (slower) | Asn3, Asn21, Asn22, Asn31, Asn35; Gln10 |
| Asp isomerization and cleavage | Asp, especially Asp-Gly, Asp-Ser, Asp-Pro | No Asp |
| Disulfide exchange | Cys | Cys2, Cys7 |
| Hydrolysis | Peptide bonds generally | Slowed by low moisture |
The right-hand column is derived from the Cagrilintide sequence. It is an inference from general chemistry, not a measured stability result. Actual stability depends on moisture, temperature, light, counterions and time.
Deamidation
Asparagine and, more slowly, glutamine side chains can lose their amide group and convert to acidic residues, adding about 1 Da to the mass and changing the charge. The reaction needs water, which is one reason dry storage matters. Cagrilintide contains no asparagine and two glutamines.1,2
Aspartate reactions
Aspartic acid can cyclize and reopen as isoaspartate, or cleave the backbone next to it. These reactions are fastest when aspartate is followed by a small or flexible residue such as glycine.2
Aggregation
Hydrophobic regions can drive molecules to associate with one another. In the dry state this is of limited consequence; in solution, hydrophobic peptides can self-associate or adsorb to surfaces, and repeated freezing and thawing can promote aggregation.1,3
Moisture is the main risk to a lyophilized powder
Lyophilized peptides are typically hygroscopic: they absorb water from the air. Absorbed moisture restarts the reactions that drying was meant to slow.2 In practice:
- Keep vials sealed until needed.
- Let a cold vial reach room temperature before opening it, so moisture does not condense on the powder.
- Minimize the time a vial is open, and reseal promptly.
Temperature and light
- Temperature: follow the storage temperature printed on the vial label. Lower temperatures slow chemical reactions; lyophilized peptides are commonly kept refrigerated or frozen for longer periods.
- Temperature cycling: repeated warming and cooling of a sealed vial is a source of condensation inside the vial. Move vials between storage temperatures as rarely as possible.
- Light: aromatic residues absorb UV light. Cagrilintide contains two phenylalanines. Store vials in their packaging or away from direct light.
Shipping
Cagrilintide ships as a dry powder, the form in which it is most stable during short periods outside controlled storage. On arrival, move vials to the storage conditions on the label.
Solutions
Peptides in solution degrade faster than dry powder. Laboratories commonly prepare only what is needed, divide solutions into single-use portions to avoid repeated freeze-thaw cycles, and record the preparation date.1
Visible signs of a problem
Changes in appearance can indicate moisture uptake or degradation and are worth noting before use:
- A collapsed, shrunken or glassy cake instead of a dry white powder.
- Discoloration, such as yellowing.
- Clumping or a sticky texture, which usually indicates absorbed moisture.
Appearance alone cannot rule out chemical change. Only repeat analysis can do that.
Stability and the certificate date
A certificate reflects the sample on its test date. It does not show how the material changes afterward. Verifying stability over time requires repeat testing with a method shown to separate degradation products from the intact peptide, such as the HPLC-UV and LC-MS methods described in HPLC analysis of Cagrilintide. Each lot's test dates are listed in the Cagrilintide testing records.
References
Published literature and guidance
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int J Pharm. 1999;185(2):129–188. PubMed 10460913. pubmed.ncbi.nlm.nih.gov/10460913/
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. Indexed in PubMed. pubmed.ncbi.nlm.nih.gov/?term=Manning+MC+Stability+of+protein+pharmaceuticals+an+update
- Instability challenges and stabilization strategies of pharmaceutical proteins. Pharmaceutics. 2022;14(11):2533. PubMed Central PMC9699111. www.ncbi.nlm.nih.gov/pmc/articles/PMC9699111/
Cagrilintide Labs analytical documentation
- Cagrilintide lot KB17122 (5 mg) certificate of analysis, Freedom Diagnostics, reported May 5, 2026. cagrilintide.bio/coa/kb17122/
- Cagrilintide lot KB17122 (5 mg) certificate of analysis, Freedom Diagnostics, reported May 5, 2026. cagrilintide.bio/coa/kb17122/
- Cagrilintide testing records, all lots. cagrilintide.bio/coa/
Published sources are limited to NIH (NCBI, PubMed, PubMed Central, PubChem) and U.S. FDA publications. Analytical documentation is first-party data from Cagrilintide certificates.